Responses
Obstetrics and gynaecology
Protocol
Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.